• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools+
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
SUBSCRIBE
2 Minute Medicine
Subscribe
EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Ask the evidence.
Get the signal.
Try it now → Physician-trained medical AI by 2 Minute Medicine
Home All Specialties Neurology

Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment

byMichael DinhandLeah Carr, MD
January 4, 2019
in Neurology, Obstetrics, Pediatrics, Public Health
Reading Time: 3 mins read
Greater prenatal alcohol exposure trajectories linked to impaired growth and neurodevelopment
Share on FacebookShare on Twitter

1. Five trajectories of prenatal alcohol exposure (PAE) were described and compared; greater PAE was associated with reduced birth weight and length, as well as lower neurodevelopmental scores at 6- and 12-month follow-up.

2. Low-to-moderate sustained alcohol exposure had persistent, larger deficits compared with early moderate-to-high exposure with reduction early in gestation, though these differences were not statistically significant.

Evidence Rating Level: 2 (Good)

Study Rundown: Prenatal alcohol exposure is known to cause growth and neurodevelopmental disorders in infants, but less is known about the relationship between PAE trajectory and its harmful effects. In this prospective cohort study, researchers interviewed pregnant women in Ukraine between 2008 and 2012 on alcohol use and measured infant neurodevelopment at 6 and 12 weeks postpartum to compare growth and neurodevelopment of infants with different PAE trajectories. Researchers grouped mothers’ alcohol use into 5 trajectories, described as minimal to no PAE throughout gestation, low-to-moderate PAE with discontinuation early in gestation, low-to-moderate PAE sustained across gestation, moderate-to-high PAE with reduction early in gestation, and high PAE sustained across gestation. Greater PAE was associated with reduced birth weight and length, as well as lower neurodevelopmental scores at 6- and 12-month follow-up. These differences persisted when controlling for multiple demographic and health factors.

These findings are limited by recall bias and a high study drop-out rate. Furthermore, researchers did not collect or control for physiologic factors, such as placental functioning, and certain sociodemographic factors may vary throughout pregnancy but were only measured once. Nonetheless, the study is strengthened by its large sample and long follow-up. For physicians, these findings highlight the importance of screening for and reducing prenatal alcohol exposure, especially among women who consume high amounts of alcohol or do not reduce use early in pregnancy.

 Click to read the study, published today in Pediatrics

RELATED REPORTS

Alcohol use declines but remains above pre-pandemic levels

Deficits in executive function are not universal among patients with alcohol use disorder

Few interventions improve posthospitalization follow-up for alcohol use disorder

Relevant reading: Prenatal Alcohol Exposure and Neurodevelopmental Disorders in Children Adopted from Eastern Europe

In-Depth [prospective cohort]: Researchers used data from the Collaborative Initiative on Fetal Alcohol Spectrum Disorders to identify 471 pregnant women at 2 prenatal care facilities in Ukraine between 2008 and 2012. Women were interviewed using standardized questionnaires about alcohol use, demographics, behavior, and pregnancy characteristics at enrollment and at ~32 weeks gestation. Information on infant growth after birth was collected from medical records, and mothers were invited at 6 and 12 weeks postpartum for neurodevelopmental assessments of infants using the Mental Developmental Index (MDI) and Psychomotor Development Index (PDI). Researchers grouped mothers’ alcohol use into 5 trajectories, described as minimal to no PAE throughout gestation, low-to-moderate PAE with discontinuation early in gestation, low-to-moderate PAE sustained across gestation, moderate-to-high PAE with reduction early in gestation, and high PAE sustained across gestation. The study compared infant growth and neurodevelopmental outcomes across trajectories.

Only sustained, high use was associated with a reduced birth weight percentile (-16.5; 95% confidence interval [CI]: -28.2 to -4.9) and length percentile (-12.6; 95% CI: -22.6 to -2.5) compared with minimal or no use after adjusting for vitamin use, SES, maternal age, and smoking. There were no significant effects observed between PAE trajectories and head circumference. Greater PAE was associated with lower neurodevelopmental scores at 6 and 12 months on the PDI and MDI. Low-to-moderate, sustained use had persistent larger deficits compared with early moderate-to-high consumption with reduction early in gestation, though these differences were not statistically significant.

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alcoholfetal alcohol syndrome (FAS)pregnancy
Previous Post

Revisional surgeries common after bariatric surgery

Next Post

Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

RelatedReports

Psychiatry

Alcohol use declines but remains above pre-pandemic levels

September 22, 2026
Chronic Disease

Deficits in executive function are not universal among patients with alcohol use disorder

September 15, 2026
Chronic Disease

Few interventions improve posthospitalization follow-up for alcohol use disorder

September 14, 2026
Prenatal antidepressant exposure may increase risk of poor motor development
Chronic Disease

Maternal use of benzodiazepines and non-benzodiazepine hypnotics is not associated with increased risk of psychiatric

May 6, 2026
Next Post
Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

Quick Take: Effect of intranasal ketamine vs. fentanyl on pain reduction for extremity injuries in children: the PRIME randomized clinical trial

PCI not superior to medical therapy alone in stable coronary disease: The COURAGE study

PCI for unprotected left main coronary artery stenosis still performed infrequently

#VisualAbstract: Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness

#VisualAbstract: Haloperidol and Ziprasidone for Treatment of Delirium in Critical Illness

EvidencePulse™ by 2 Minute Medicine 2026 evidence scan 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... ↑ Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Prognostic associations of anthropometric indices vary by clinical outcomes
  • Anitocabtagene autoleucel associated with sustained clinical response in heavily pretreated multiple myeloma
  • Gene therapy shows sustained benefit in Wiskott–Aldrich syndrome
License Content
Terms of Use | Disclaimer
Cookie Policy
Cleantalk Pixel
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters

Already a member? Sign in

  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Tools
    • EvidencePulse™
    • HypeCheck™
    • NPI Registry Lookup
    • RVU Search
  • Pharma
  • AI Roundup
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • My account
    • Cart
    • Sign-in
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.